Translational Session
Therapeutic Landscape for the Management of Diabetic Kidney Disease: What's Next After SGLT2 Inhibition?
November 06, 2025 | 10:30 AM - 12:30 PM
Location: General Assembly C, Convention Center
Session Description
Despite improvements in therapy for diabetic kidney disease (DKD), new therapies remain necessary to optimize patient prognosis. This session reviews new targets and approaches for the treatment of DKD.
Learning Objective(s)
- Describe the use of mineralocorticoid receptor agonists and aldosterone synthase inhibitors in the treatment of DKD
- Explain the importance of the soluble guanylyl cyclase pathway for proper endothelial health
- Identify mechanisms of fluid retention observed with endothelin receptor antagonists and explain how SGLT2 inhibitors can mitigate this
Learning Pathway(s)
- Diabetic Kidney Disease
Moderators
Presentations
- New Insights in Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors
10:30 AM - 11:00 AM
- Soluble Guanylyl Cyclase Inhibitors: Improving Endothelial Function and Kidney Outcomes
11:00 AM - 11:30 AM
- Endothelin Receptor Antagonists: Can We Optimize Their Use by Adding to SGLT2 Inhibitors?
11:30 AM - 12:00 PM
- Novel Therapeutic Targets for DKD
12:00 PM - 12:30 PM